123 related articles for article (PubMed ID: 30485422)
1. Reasons for nonadherence and response to treatment in an adherence intervention trial for relapsing-remitting multiple sclerosis patients.
Schoor R; Bruce A; Bruce J; Goggin K; Schanfarber B; Bradley-Ewing A; Thelen J; Glusman M; Lynch SG; Strober L; Catley D
J Clin Psychol; 2019 Mar; 75(3):380-391. PubMed ID: 30485422
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study.
Lenz F; Harms L
Adv Ther; 2020 Jun; 37(6):2999-3009. PubMed ID: 32333326
[TBL] [Abstract][Full Text] [Related]
3. Medication adherence to disease-modifying therapies among a cohort of Jordanian patients with relapsing-remitting multiple sclerosis: a multicentre cross-sectional study.
Al-Keilani MS; Almomani BA
Int J Pharm Pract; 2023 Apr; 31(2):198-205. PubMed ID: 36738264
[TBL] [Abstract][Full Text] [Related]
4. A pilot study to improve adherence among MS patients who discontinue treatment against medical advice.
Bruce J; Bruce A; Lynch S; Strober L; O'Bryan S; Sobotka D; Thelen J; Ness A; Glusman M; Goggin K; Bradley-Ewing A; Catley D
J Behav Med; 2016 Apr; 39(2):276-87. PubMed ID: 26563147
[TBL] [Abstract][Full Text] [Related]
5. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.
Burt RK; Balabanov R; Burman J; Sharrack B; Snowden JA; Oliveira MC; Fagius J; Rose J; Nelson F; Barreira AA; Carlson K; Han X; Moraes D; Morgan A; Quigley K; Yaung K; Buckley R; Alldredge C; Clendenan A; Calvario MA; Henry J; Jovanovic B; Helenowski IB
JAMA; 2019 Jan; 321(2):165-174. PubMed ID: 30644983
[TBL] [Abstract][Full Text] [Related]
6. A randomized controlled multimodal behavioral intervention trial for improving antiepileptic drug adherence.
Pakpour AH; Gholami M; Esmaeili R; Naghibi SA; Updegraff JA; Molloy GJ; Dombrowski SU
Epilepsy Behav; 2015 Nov; 52(Pt A):133-42. PubMed ID: 26414343
[TBL] [Abstract][Full Text] [Related]
7. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
Yano H; Gonzalez C; Healy BC; Glanz BI; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2019 Oct; 35():119-127. PubMed ID: 31374460
[TBL] [Abstract][Full Text] [Related]
8. Cost avoidance from health system specialty pharmacist interventions in patients with multiple sclerosis.
Georgieva D; Markley B; DeClercq J; Choi L; Zuckerman AD
J Manag Care Spec Pharm; 2024 Apr; 30(4):336-344. PubMed ID: 38555624
[TBL] [Abstract][Full Text] [Related]
9. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.
Gajofatto A; Bacchetti P; Grimes B; High A; Waubant E
Mult Scler; 2009 Jan; 15(1):50-8. PubMed ID: 18922831
[TBL] [Abstract][Full Text] [Related]
10. Stoppers and non-starters of disease-modifying treatment in multiple sclerosis.
Grytten N; Aarseth JH; Espeset K; Johnsen GB; Wehus R; Lund C; Haugstad RC
Acta Neurol Scand; 2013 Feb; 127(2):133-40. PubMed ID: 22924678
[TBL] [Abstract][Full Text] [Related]
11. Discontinuing Treatment Against Medical Advice: The Role of Perceived Autonomy Support From Providers in Relapsing-Remitting Multiple Sclerosis.
Glusman M; Bruce A; Thelen J; Smith J; Lynch S; Catley D; Bennett KK; Bruce J
Ann Behav Med; 2019 Mar; 53(3):283-289. PubMed ID: 29771271
[TBL] [Abstract][Full Text] [Related]
12. Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study).
Patti F; Chisari CG; D'Amico E; Annovazzi P; Banfi P; Bergamaschi R; Clerici R; Conti MZ; Cortese A; Fantozzi R; Fischetti M; Frigo M; Gatto M; Immovilli P; Leoni S; Malucchi S; Maniscalco G; Marfia GA; Paolicelli D; Perini P; Serrati C; Sola P; Totaro R; Turano G; Valentino P; Zaffaroni M; Zuliani C; Centonze D
Mult Scler Relat Disord; 2020 Jul; 42():102124. PubMed ID: 32353755
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Bonafede MM; Johnson BH; Wenten M; Watson C
Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
[TBL] [Abstract][Full Text] [Related]
14. Reasons patients give to use or not to use immunomodulating agents for multiple sclerosis.
Visser LH; van der Zande A
Eur J Neurol; 2011 Nov; 18(11):1343-9. PubMed ID: 21496180
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study.
Simacek KF; Ko JJ; Moreton D; Varga S; Johnson K; Katic BJ
J Med Internet Res; 2018 Oct; 20(10):e11168. PubMed ID: 30377144
[TBL] [Abstract][Full Text] [Related]
16. Non-compliance with disease modifying therapies in patients with Multiple Sclerosis: A qualitative analysis.
Stratos K; McGarragle K; Thistle J; Vyas MV; Lee L
Mult Scler Relat Disord; 2020 Jun; 41():102016. PubMed ID: 32135497
[TBL] [Abstract][Full Text] [Related]
17. Injectable disease-modifying therapy for relapsing-remitting multiple sclerosis: a review of adherence data.
Caon C; Saunders C; Smrtka J; Baxter N; Shoemaker J
J Neurosci Nurs; 2010 Oct; 42(5 Suppl):S5-9. PubMed ID: 21049828
[TBL] [Abstract][Full Text] [Related]
18. Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate.
Ziemssen T; Gilgun-Sherki Y
BMC Neurol; 2015 Oct; 15():189. PubMed ID: 26450155
[TBL] [Abstract][Full Text] [Related]
19. Baseline predictors of DMT reinitiation among patients with multiple sclerosis following an MI-CBT intervention.
Thelen J; Bruce A; Catley D; Lynch S; Goggin K; Bradley-Ewing A; Glusman M; Norouzinia A; Strober L; Bruce J
J Behav Med; 2018 Apr; 41(2):253-260. PubMed ID: 29124557
[TBL] [Abstract][Full Text] [Related]
20. Associations Between Treatment Satisfaction, Medication Beliefs, and Adherence to Disease-Modifying Therapies in Patients with Multiple Sclerosis.
Thach AV; Brown CM; Herrera V; Sasane R; Barner JC; Ford KC; Lawson KA
Int J MS Care; 2018; 20(6):251-259. PubMed ID: 30568562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
